Schrödinger is a leading physics-based computational platform that transforms the way therapeutics and materials are discovered. Founded in 1990, the company has pioneered advanced molecular modeling and simulation technologies used by the world's top pharmaceutical and biotech companies.
The platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration across two main domains:
Life Science Solutions: Schrödinger's drug discovery platform includes industry-leading tools such as Maestro (molecular modeling interface), Glide (molecular docking with 98% pose accuracy), FEP+ (free energy calculations), LiveDesign (collaborative design platform), and BioLuminate (biologics tools). These solutions enable structure prediction, target validation, hit identification, lead optimization, and accelerated drug discovery cycles through simulation-driven approaches.
Materials Science Solutions: The materials science platform features MS Maestro, Desmond (molecular dynamics), Jaguar (quantum chemistry), and MS LiveDesign for polymer research, electronics development, and catalyst design.
Key Capabilities:
- In silico molecular property predictions with physics-based accuracy
- Chemical space exploration across extensive molecular libraries
- Molecular dynamics simulations for biologics and small molecules
- AI-powered next best action recommendations
- Collaborative design workflows with LiveDesign platform
- Python API for custom workflow integration
Schrödinger serves the top 20 pharmaceutical companies by revenue, numerous biotech startups, academic institutions, and government laboratories across more than 70 countries. The company employs approximately 900 people across 12 global offices and has received recognition as America's #1 Most Loved Workplace in Pharma/Biotech by Newsweek (2022).
The platform is trusted by leading organizations including Bayer, Takeda, Merck, and Agios Pharmaceuticals for developing FDA-approved medicines enabled by computational design. Schrödinger also co-founded Nimbus Therapeutics, demonstrating the platform's effectiveness in accelerating drug discovery from concept to clinic.